Emergent Biosolutions Receivables 2010-2025 | EBS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Emergent Biosolutions receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Emergent Biosolutions receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.1B
Amgen (AMGN)	$155.2B
Gilead Sciences (GILD)	$148.2B
Vertex Pharmaceuticals (VRTX)	$94B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$82.7B
GSK (GSK)	$77.1B
Regeneron Pharmaceuticals (REGN)	$59.7B
Alnylam Pharmaceuticals (ALNY)	$57.5B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$26.8B
Insmed (INSM)	$23.2B
Royalty Pharma (RPRX)	$21.1B
Biogen (BIIB)	$19.2B
Incyte (INCY)	$15.3B
Illumina (ILMN)	$14.5B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.7B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Moderna (MRNA)	$10.2B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Exact Sciences (EXAS)	$7.8B
Halozyme Therapeutics (HALO)	$7.8B